Adverse bioeffects of ultrasound contrast agents used in echocardiography: True safety issue or "much ado about nothing"?

Current Vascular Pharmacology

Volumn 7, Issue 3, 2009, Pages 338-346

  Aggeli, Constadina ^a,b   Giannopoulos, Georgios ^a   Lampropoulos, Konstantinos ^a   Pitsavos, Christos ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Contrast echocardiography; Coronary artery disease; Safety; Ultrasound contrast agents

Indexed keywords

ALBUNEX; DOBUTAMINE; ECHO CONTRAST MEDIUM; FIBRINOLYTIC AGENT; FLUOROCARBON; LACTIC ACID; PERFLUTREN; SHU 508; SONOVUE; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

BLOOD VESSEL INJURY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSTIC IMAGING; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; GAS; HEART LEFT VENTRICLE; HEART MUSCLE BLOOD FLOW; HUMAN; IMAGE ENHANCEMENT; ISOLATED HEART; MEDICAL DOCUMENTATION; MICROBUBBLE; NONHUMAN; RADIATION BEAM; RADIATION ENERGY; REVIEW; STRESS ECHOCARDIOGRAPHY; TISSUE DOPPLER IMAGING; ULTRASOUND; ANIMAL; DRUG EFFECT; DRUG SCREENING; HEART; HEMOLYSIS; METHODOLOGY; MICROCIRCULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; DRUG EVALUATION, PRECLINICAL; ECHOCARDIOGRAPHY; HEART; HEMOLYSIS; HUMANS; MICROBUBBLES; MICROCIRCULATION; MUSCLE, SMOOTH, VASCULAR;

EID: 69149089539     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109788340695     Document Type: Review

References (82)

1. De Jong N, Ten Cate FJ. New ultrasound contrast agents and technological innovations. Ultrasonics 1996; 34: 587-90.
2. Kaul S. Myocardial contrast echocardiography. 15 years of research and development. Circulation 1997; 96: 3745-60.
3. Kaul S, Pandian NG, Okada RD, Pohost GM, Weyman AE. Contrast echocardiography in acute myocardial ischemia: I. In-vivo determination of total left ventricular "area at risk." J Am Coll Cardiol 1984; 4: 1272-82.
4. Perchet H, Dupouy P, Duval-Moulin AM, Hittinger L, Pelle G, Brun P, et al. Improvement of subendocardial myocardial perfusion after percutaneous transluminal coronary angioplasty: a myocardial contrast echocardiography study with correlation between myocardial contrast reserve and Doppler coronary reserve. Circulation 1995; 91: 1419-26.
5. Sabia PJ, Powers ER, Jayaweera AR, Ragosta M, Kaul S. Functional significance of collateral blood flow in patients with recent acute myocardial infarction: a study using myocardial contrast echocardiography. Circulation 1992; 85: 2080-9.
6. Ragosta M, Camarano G, Kaul S, Powers ER, Sarembock IJ, Gimple LW. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction: new insights using myocardial contrast echocardiography. Circulation 1994; 89: 2562-9.
7. Rovai D, Zanchi M, Lombardi M, Magagnini E, Chella P, Pieroni A, et al. Residual myocardial perfusion in reversibly damaged myocardium by dipyridamole contrast echocardiography. Eur Heart J 1996; 17: 296-301.
8. Meza MF, Ramee S, Collins T, Stapleton D, Milani RV, Murgo JP, et al. Knowledge of perfusion and contractile reserve improves the predictive value of recovery of regional myocardial function post-revascularization: a study using the combination of myocardial contrast echocardiography and dobutamine echocardiography. Circulation 1997; 96: 3459-65.
9. Nagueh SF, Vaduganathan P, Ali N, Blaustein A, Verani MS, Winters WL Jr, et al. Identification of hibernating myocardium: comparative accuracy of myocardial contrast echocardiography, rest-redistribution thallium-201 tomography and Dobutamine echocardiography. J Am Coll Cardiol 1997; 29: 985-93.
10. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-705.
11. Bolognese L, Antoniucci D, Rovai D, Buonamici P, Cerisano G, Santoro GM, et al. Myocardial contrast echocardiography vs dobutamine echocardiography for predicting functional recovery after acute myocardial infarction treated with primary coronary angioplasty. J Am Coll Cardiol 1996; 28: 1677-83.
12. Holmes DR Jr, Valeti VS, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Interv 2005; 66: 375-89.
13. Reisner SA, Ong LS, Lichtenberg GS, Shapiro JR, Amico AF, Allen MN, et al. Quantitative assessment of the immediate results of coronary angioplasty by myocardial contrast echocardiography. J Am Coll Cardiol 1989; 12: 852-6.
14. Lang RM, Feinstein SB, Feldman T, Neumann A, Chua KG, Borow KM. Contrast echocardiography for the evaluation of myocardial perfusion: effects of coronary angioplasty. J Am Coll Cardiol 1986; 8: 232-5.
15. Porter TR, D'Sa A, Pesko L, Turner C, Nath A, Vetrovec GW, et al. Usefulness of myocardial contrast echocardiography in detecting the immediate changes in anterograde blood flow reserve after coronary angioplasty. Am J Cardiol 1993; 71: 893-6.
16. Meza MF, Mobarek S, Sonnemaker R, Shuler S, Ramee SR, Collins TJ, et al. Myocardial contrast echocardiography in human beings: correlation of resting perfusion defects to sestamibi single photon emission computed tomography. Am Heart J 1996; 132: 528-35.
17. Shimoni S, Zoghbi WA, Xie F, Kricsfeld D, Iskander S, Gobar L, et al. Real-time assessment of myocardial perfusion and wall motion during bicycle and treadmill exercise echocardiography: comparison with single photon emission computed tomography. J Am Coll Cardiol 2001; 37: 741-7.
18. Elhendy A, O'Leary EL, Xie F, McGain AC, Anderson JR, Porter TR. Comparative accuracy of real-time myocardial contrast perfusion imaging and wall motion analysis during dobutamine stress echocardiography for the diagnosis of coronary artery disease. J Am Coll Cardiol 2004; 44: 2185-91.
19. Aggeli C, Giannopoulos G, Misovoulos P, Roussakis G, Christoforatou E, Kokkinakis C, et al. Real-time three-dimensional dobutamine stress echocardiography for coronary artery disease diagnosis: validation with coronary angiography. Heart 2007; 93: 672-5.
20. Dittrich HC, Bales GL, Kuvelas T, Hunt RM, McFerran BA, Greener Y. Myocardial contrast echocardiography in experimental coronary artery occlusion with a new intravenously administered contrast agent. J Am Soc Echocardiogr 1995; 8: 465-74.
21. Meza M, Greener Y, Hunt R, Perry B, Revall S, Barbee W, et al. Myocardial contrast echocardiography: reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent. Am Heart J 1996; 132: 871-81.
22. Firschke C, Lindner JR, Wei K, Goodman NC, Skyba DM, Kaul S. Myocardial perfusion imaging in the setting of coronary artery stenosis and acute myocardial infarction using venous injection of a second-generation echocardiographic contrast agent. Circulation 1997; 96: 959-67.
23. Main J, Escobar JF, Hall SA, Killam AL, Grayburn PA. Detection of myocardial perfusion defects by contrast echocardiography in the setting of acute myocardial ischemia with residual antegrade flow. J Am Soc Echocardiogr 1998; 11: 228-35.
24. Rovai D, Lubrano V, Vassalle C, Paterni M, Marini C, Kozakova M, et al. Detection of perfusion defects during coronary occlusion and myocardial reperfusion after thrombolysis by intravenous administration of the echoenhancing agent BR1. J Am Soc Echocardiogr 1998; 11: 169-80.
25. Lindner J, Firschke C, Wei K, Goodman C, Skyba DM, Kaul S. Myocardial perfusion characteristics and hemodynamic profile of MRX-115, a venous echocardiographic contrast agent, during acute myocardial infarction. J Am Soc Echocardiogr 1998; 11: 36-46.
26. Wei K, Skyba DM, Firschke C, Jayaweera AR, Lindner JR, Kaul S. Interactions between microbubbles and ultrasound: in vitro and in vivo observations. J Am Coll Cardiol 1997; 29: 1081-8.
27. Skyba DM, Price RJ, Linka AZ, Skalak TC, Kaul S. Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation 1998; 98: 290-3.
28. Dayton PA, Morgan KE, Klibanov AL, Brandenburger GH, Ferrara KW. Optical and acoustical observations of the effects of ultrasound on contrast agents. IEEE Trans 1999; 46: 220-32.
29. Dalecki D, Child SZ, Reaman CH, Cox C, Penney DP, Carstensen EL. Age-dependence of ultrasonically-induced lung hemorrhage in mice. Ultrasound Med Biol 1997; 23: 767-76.
30. Price RJ, Skyba DM, Kaul S, Skalak TC. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation 1998; 98: 1264-7.
31. Carstensen EL, Duck FA, Meltzer RS, Schwarz KQ, Keller B. Bioeffects in echocardiography. Echocardiography 1992; 9: 605-23.
32. Dalecki D. WFUMB safety symposium on Echo-Contrast Agents: bioeffects of ultrasound contrast agents in vivo. Ultrasound Med Biol 2007; 33: 205-13.
33. Dalecki D, Keller BB, Carstensen EL, Neel DS, Palladino JL, Noordergraaf A. Thresholds for premature ventricular contractions in frog hearts exposed to lithotripter fields. Ultrasound Med Biol 1991; 17: 341-6.
34. Dalecki D, Child SZ, Raeman CH, Cox C, Penney DP, Carstensen EL. Age dependence of ultrasonically induced lung hemorrhage in mice. Ultrasound Med Biol 1997; 23: 767-76.
35. Porter TR, Xie F. Therapeutic ultrasound for gene delivery. Echocardiography 2001; 18: 349-53.
36. Price RJ, Skyba DM, Kaul S, Skalak TC. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation 1998; 98: 1264-7.
37. Chen S, Kroll MH, Shohet RV, Frenkel P, Mayer SA, Grayburn PA. Bioeffects of myocardial contrast microbubble destruction by echocardiography. Echocardiography 2002; 19: 495-500.
38. Unger EC, Hersh E, Vannan M, Matsunaga TO, McCreery T. Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis 2001; 44: 45-54.
39. Ay T, Havaux X, Van Camp G, Campanelli B, Gisellu G, Pasquet A, et al. Destruction of contrast microbubbles by ultrasound: effects on myocardial function, coronary perfusion pressure, and microvascular integrity. Circulation 2001; 104: 461-6.
40. Miller DL, Gies RA. The influence of ultrasound frequency and gasbody composition on the contrast agent-mediated enhancement of vascular bioeffects in mouse intestine. Ultrasound Med Biol 2000; 26: 307-13.
41. MacRobbie AG, Raeman CH, Child SZ, Dalecki D. Thresholds for premature contractions in murine hearts exposed to pulsed ultrasound. Ultrasound Med Biol 1997; 23: 761-5.
42. Dalecki D, Raeman CH, Child SZ, Carstensen EL. Effects of pulsed ultrasound on the frog heart: III. The radiation force mechanism. Ultrasound Med Biol 1997; 23: 275-85.
43. Killam AL, Greener Y, McFerran BA, Maniquis J, Bloom A, Widder KJ, et al. Lack of bioeffects of ultrasound energy after intravenous administration of FS069 (Optison) in the anesthetized rabbit. J Ultrasound Med 1998; 17: 349-56.
44. Miller DL, Gies RA. Gas-body-based contrast agent enhances vascular bioeffects of 1.09 MHz ultrasound on mouse intestine. Ultrasound Med Biol 1998; 24: 201-8.
45. Miller DL, Gies RA. The influence of ultrasound frequency and gasbody composition on the contrast agent-mediated enhancement of vascular bioeffect in mouse intestine. Ultrasound Med Biol 2000; 26: 307-13.
46. Skyba DM, Price RJ, Linka AZ, Skalak TC, Kaul S. Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation 1998; 98: 290-3.
47. Miller DL, Quddus J. Diagnostic ultrasound activation of contrast agent gas bodies induces capillary rupture in mice. Proc Nat Acad Sci 2000; 97: 10179-84.
48. Song J, Qi M, Kaul S, Price RJ. Stimulation of arteriogenesis in skeletal muscle by microbubble destruction with ultrasound. Circulation 2002; 106: 1550-5.
49. Kobayashi N, Yasu T, Yamada S, Kudo N, Kuroki M, Kawakami M, et al. Endothelial cell injury in venule and capillary induced by contrast ultrasonography. Ultrasound Med Biol 2002; 28: 949-56.
50. Kobayashi N, Takanori Y, Yamada S, Kudo N, Kuroki M, Miyatake K, et al. Influence of contrast ultrasonography with perflutren lipid microspheres on microvessel injury. Circ J 2003; 67: 630-6.
51. Hwang JH, Brayman AA, Reidy MA, Matula TJ, Kimmey MB, Crum LA. Vascular effects induced by combined 1-MHz ultrasound and microbubble contrast agent treatments in vivo. Ultrasound Med Biol 2005; 31: 553-64.
52. Wible JH, Galen KP, Wojdyla JK, Hughes MS, Klibanov AL, Brandenburger GH. Microbubbles induce renal haemorrhage when exposed to diagnostic ultrasound in anesthetized rats. Ultrasound Med Biol 2002; 28: 1535-46.
53. AIUM (American Institute of Ultrasound in Medicine). Mechanical bioeffects in the presence of gas-carrier ultrasound contrast agents. J Ultrasound Med 2000; 19: 120-42.
54. Carstensen EL, Gracewski S, Dalecki D. The search for cavitation in vivo. Ultrasound Med Biol 2000; 26: 1377-85.
55. Raeman CH, Child SZ, Meltzer RS, Carstensen EL. Albunex® does not increase the sensitivity of the lung to pulsed ultrasound. Echocardiography 1997; 14: 553-7.
56. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Non-invasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001; 220: 640-6.
57. Schlachetzki F, Holscher T, Koch HJ, Draganski B, May A, Schuierer G, et al. Observation on the integrity of the blood-brain barrier after microbubble destruction by diagnostic transcranial color-coded sonography. J Ultrasound Med 2002; 21: 419-29.
58. MacRobbie AG, Raeman CH, Child SZ, Dalecki D. Thresholds for premature contractions in murine hearts exposed to pulsed ultrasound. Ultrasound Med Biol 1997; 23: 761-5.
59. van der Wouw PA, Brauns AC, Bailey SE, Powers JE. Premature ventricular contractions during triggered imaging with ultrasound-contrast. J Am Soc Echocardiogr 2000; 13: 288-94.
60. Optison,(Human Albumin Microsphers) Injectable Suspension Octafluoropropane Formulation. Manufacturer's product insert. Mallinckrodt, Inc. St. Louis, MO October 2000.
61. Definity, (Perflutren Lipid Microspheres) Vial for Injectable Suspensions. Manufacturer's product description insert. Bristol-Myers Squibb Medical Imaging, Inc. Billerica, MA. March 2002.
62. Dalecki D, Rota C, Raeman CH, Child SZ. Premature cardiac contractions produced by ultrasound and microbubble contrast agents in mice. Acoust Res Let Online 2005; 6: 221-5.
63. Zachary JF, Hartleben S, Frizzell LA, O'Brien WD. Arrhythmias in rat hearts exposed to pulsed ultrasound after intravenous injection of a contrast agent. J Ultrasound Med 2002; 21: 1347-56.
64. Chen SY, Kroll MH, Shohet RV, Frenkel P, Mayer SA, Grayburn PA. Bioeffects of myocardial contrast microbubble destruction by echocardiography. Echocardiography 2002; 19: 495-500.
65. Birnbaum Y, Luo H, Nagai T, Fishbein MC, Peterson TM, Li S, et al. Noninvasive in vivo clot dissolution without a thrombolytic drug: Recanalization of thrombosed iliofemoral arteries with transcutaneous ultrasound combined with intravenous infusion of microbubbles. Circulation 1998; 97: 130-4.
66. Zachary JF, Hartleben S, Frizzell LA, O'Brien WD. Arrhythmias in rat hearts exposed to pulsed ultrasound after intravenous injection of a contrast agent. J Ultrasound Med 2002; 21: 1347-1356.
67. Culp WC, Porter TR, Xie F, Goertzen TC, McCowan TC, Vonk BN, et al. Microbubble potentiated ultrasound as a method of declotting thrombosed dialysis grafts: experimental study in dogs. Cardiov Intervent Radiol 2001; 24: 407-12.
68. Cohen JL, Cheirif J, Segar DS, Gillam LD, Gottdiener JS, Hausnerova E, et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial. J Am Coll Cardiol 1998; 32: 746-52.
69. Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (Definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000; 86: 669-74.
70. Skyba DM, Camarano G, Goodman NC, Price RJ, Skalack TC, Kaul S. Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection. J Am Coll Cardiol 1996; 28: 1292-300.
71. Borges AC, Walde T, Reibis RK, Grohmann A, Ziebig R, Rutsch W, et al. Does contrast echocardiography with Optison induce myocardial necrosis in humans? J Am Soc Echocardiogr 2002; 15(10 Pt 1): 1080-6.
72. Cosyns B, Weytjens C, Vanderhoogstrate M, Daniels C, Schoors D, Van Camp G. Tissue doppler imaging does not show infraclinical alteration of myocardial function after contrast echocardiography. Eur J Echocardiogr 2005; 6: 238-42.
73. Vancraeynest D, Kefer J, Hanet C, Fillee C, Beauloye C, Pasquet A, et al. Release of cardiac bio-markers during high mechanical index contrast-enhanced echocardiography in humans. Eur Heart J 2007; 28: 1236-41.
74. Tsutsui JM, Elhendy A, Xie F, O'Leary EL, McGrain AC, Porter TR. Safety of dobutamine stress real-time myocardial contrast echocardiography. J Am Coll Cardiol 2005; 45: 1235-42.
75. Aggeli C, Giannopoulos G, Roussakis G, Christoforatou E, Marinos G, Toli C, et al. Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for detection of ischemia in 5250 studies. Heart 2008; 94: 1571-7.
76. Dolan MS, Riad K, El-Shafei A, Puri S, Tamirisa K, Bierig M, et al. Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients. Am Heart J 2001; 142: 908-15.
77. Senior R, Lepper W, Pasquet A, Chung G, Hoffman R, Vanoverschelde JL, et al. Myocardial perfusion assessment in patients with medium probability of coronary artery disease and no prior myocardial infarction: comparison of myocardial contrast echocardiography with 99mTc single-photon emission computed tomography. Am Heart J 2004; 147: 1100-5.
78. Tsutsui JM, Elhendy A, Anderson JR, Xie F, McGrain AC, Porter TR. Prognostic value of dobutamine stress myocardial contrast perfusion echocardiography. Circulation 2005; 112: 1444-50.
79. Main ML, Goldman JH, Grayburn PA. Thinking outside the "box"-the ultrasound contrast controversy. J Am Coll Cardiol 2007; 50: 2434-7.
80. Grayburn PA. Product safety compromises patient safety (an unjustified black box warning on ultrasound contrast agents by the Food and Drug Administration). Am J Cardiol 2008; 101: 892-3.
81. Hayat SA, Senior R. Myocardial contrast echocardiography in ST elevation myocardial infarction: ready for prime time? Eur Heart J 2008; 29: 299-314.
82. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/forms/u]CTCAEv3.pdf.